What precautions should be taken while taking regorafenib?

Regorafenib is a targeted drug used to treat colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma. While patients are using regorafenib, special attention needs to be paid to some potential adverse reactions and precautions to ensure the safety and effectiveness of the treatment.

1. Hepatotoxicity is one of the side effects that requires careful monitoring when using regorafenib. In clinical trials, some patients suffered severe drug-induced liver injury, even leading to death. In most cases, this type of liver dysfunction occurs during the first two months of treatment and manifests as liver cell damage. Therefore, during the treatment process, liver function tests must be performed regularly. If abnormal liver function test results are found, a decision should be made based on the severity of hepatotoxicity whether to temporarily discontinue the drug, reduce the dose, or permanently discontinue the drug.

2.Infection is also a common complication during regorafenib treatment. Patients may experience urinary tract infections, nasopharyngitis, skin and mucosal infections, systemic fungal infections, and pneumonia. Particularly in patients receiving regorafenib, mortality due to infection was higher than in the placebo group, so treatment should be discontinued immediately for serious Grade 3 or 4 infections, or for any grade of exacerbation of infection. Only after the infection symptoms are relieved can the original dose of regorafenib be considered.

3.The risk of bleeding also deserves attention. Studies have shown that regorafenib use is associated with an increased incidence of bleeding events, especially severe or life-threatening bleeding, and patients should permanently discontinue the drug. In addition, patients receiving warfarin need to monitor their INR levels more frequently to prevent an increased risk of bleeding.

4. Gastrointestinal perforation or fistula is another important adverse reaction of regorafenib. Across all clinical trials, gastrointestinal perforation was reported in 0.6% of patients, including eight fatal cases. If a patient develops such complications, regorafenib should be permanently discontinued.

5. Skin toxicity is another common side effect of regorafenib, including hand-foot skin reaction (HFSR) and severe rash. Although the probability of toxic epidermal necrolysis is low, once severe skin reactions occur, the decision to discontinue the drug or adjust the dose must be based on the severity of the disease.

6. Hypertension is also an important problem in regorafenib treatment. Most patients will develop symptoms of hypertension within the first treatment cycle. Therefore, ensure blood pressure is controlled before starting regorafenib and monitor blood pressure weekly during the first six weeks of treatment and thereafter as clinically indicated. If severe or uncontrolled hypertension is encountered, temporary or permanent discontinuation of the drug should be considered.

7. The risk of cardiac ischemia and infarction cannot be ignored. If the patient develops new or acute myocardial ischemia or infarction, regorafenib needs to be discontinued immediately. Resumption of this drug should be considered after resolution of the acute event only if it is determined that the potential benefits outweigh the cardiac risks.

8. In addition, reversible posterior leukoencephalopathy syndrome (RPLS) may also occur in patients taking regorafenib. This is a disease diagnosed through characteristic MRI findings. Patients who develop symptoms such as seizures, severe headaches, visual disturbances, or confusion should be promptly evaluated. If RPLS is diagnosed, regorafenib must be discontinued.

9. Impaired wound healing is also a concern during regorafenib treatment. Because this drug inhibits the VEGF signaling pathway, it may cause wound healing disorders. Therefore, patients scheduled to undergo elective surgery should stop taking regorafenib for at least two weeks before surgery and not take it for at least two weeks after major surgery until the wound has completely healed.

To sum up, various potential adverse reactions need to be treated with caution in the clinical application of regorafenib. Doctors should regularly evaluate the patient's health status and take corresponding measures in a timely manner to ensure the patient's safety and therapeutic effect.

Reference materials:https://www.stivarga-us.com/